About STADA Group
STADA Group is a leading healthcare and pharmaceuticals company that specializes in Consumer Healthcare, Generics, and Specialty Pharmaceuticals. The company is a manufacturer of high-quality pharmaceuticals with a rich history of 130 years, headquartered in Bad Vilbel, Germany.
25,000+ products
worldwide, of which 8,000 are Consumer Healthcare products – built on around 800 APIs (Active Pharmaceutical Ingredient)
100+ countries
The product is sold in over 100 countries worldwide
11,650+ employees
across 88 countries globally, with women holding 51% of management positions
500+ partners
in development & production globally
Top 4
STADA ranks as the fourth-largest player by gross sales in Europe in the market for Generics and Consumer Healthcare products
17 production sites
located in 11 countries across Europe (Austria, Bosnia-Herzegovina, Czech Republic, Germany, Montenegro, Romania, Serbia, UK, Ukraine) and Asia – including 2 strategic plants of STADA Pymepharco in Vietnam.
STADA has a geographically diversified and effective manufacturing footprint
STADA focuses on a three-pillar strategy including Consumer Healthcare, Generics, and Specialty Pharmaceuticals.
Consumer healthcare brands such as Zoflora®, Grippostad®, SNUP®, Silomat® and Hirudoid® are among the top sellers in their respective product categories. In financial year 2024, STADA achieved group sales of EUR 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of EUR 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide.
Since 2002, STADA Group has made significant investments in Vietnam, particularly through the full acquisition of Pymepharco JSC (now referred to as STADA Pymepharco) in 2021.
2021
2020
2019
2017
2017
2008
2002
2021
- STADA Group officially acquired 99.99% of Pymepharco's shares, making the company its sole wholly owned affiliate member in Vietnam.
- Since then, Pymepharco has gradually transitioned into STADA Pymepharco, fully aligning with STADA Group’s global standards and vision.
- As part of the Group’s international network, STADA Pymepharco is dedicated to delivering high-quality, globally recognized healthcare solutions to patients in Vietnam and beyond.
2020
- STADA Group increased its ownership in Pymepharco to 88%.
2019
- As part of the capital acquisition roadmap, STADA-Vietnam Joint Venture Company Limited (STADA-VN J.V.) underwent a name change.
- STADA Group no longer holds any legal affiliation with this company.
2017
- STADA Group increased its ownership in Pymepharco to 72%
2017
- STADA Group withdrew all shares in STADA Vietnam Joint Venture Company Limited (STADA-VN J.V Company)
- Since then, STADA Group officially ended its participation in this joint venture.
2008
STADA Group became a strategic shareholder in Pymepharco with a 51% ownership stake.
2002
- STADA Group and M.S.T contributed capital 50-50 and established STADA Vietnam Joint Venture Company Limited (STADA-VN J.V Company)
